Culture method of urinary system tumor primary cells
By using collagen-coated culture flasks and hypoxic conditions, combined with CRISPR-Cas9 gene editing and 3D model, the problem of poor cell stability in traditional methods is solved, the tumor microenvironment is simulated, and more accurate drug screening and personalization is achieved. The basis of treatment provides a more effective method for tumor research.
Patent Information
- Application Number
- CN202411251215.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-07
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The traditional primary cell culture method of urinary tract tumors has problems such as low cell survival rate, poor stability and difficulty in mimicking the tumor microenvironment, which limits its application in tumor research.
The collagen-coated culture flask and adapted medium formula were used, combined with hypoxic culture conditions, gene editing was performed using the CRISPR-Cas9 system, and the structure and growth mode of tumor tissue were simulated through 3D culture model and single-cell RNA sequencing technology. In-depth analysis of cell heterogeneity.
It improves the stability and repeatability of primary cells of urinary tumors, simulates the tumor microenvironment, provides a more accurate drug screening platform and the basis for personalized treatment, and helps reveal key genes and pathways in tumor development.
Smart Images

Figure CN118909955A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of primary tumor cell culture, and particularly relates to a method for culturing primary urinary system tumor cells. Background Art
[0002] With the continuous progress of medicine and biotechnology, the treatment and research of urinary tumors are facing great challenges and opportunities. As an important means to study the biological characteristics, gene function and drug responsiveness of tumors, the culture of primary cells of urinary tumors plays a vital role in understanding the mechanism of tumor development, discovering new therapeutic targets and evaluating the therapeutic effect.
[0003] Traditional methods for culturing primary cells of urinary system tumors often have problems such as low cell survival rate, poor stability, and difficulty in simulating the tumor microenvironment, which limit their application in tumor research. In order to overcome these limitations, the inventors proposed a method for culturing primary cells of urinary system tumors to solve the above problems. Summary of the invention
[0004] The object of the present invention is to provide a method for culturing primary cells of urinary system tumors to solve the problems raised in the above background technology.
[0005] To achieve the above object, the present invention provides the following technical solutions:
[0006] A method for culturing primary cells of urinary system tumors comprises the following steps:
[0007] S1. Tissue sample collection and processing: obtain urinary tract tumor tissue from surgery, place the tissue in a sterile container containing cold PBS, and quickly send it to the laboratory;
[0008] S2. Tissue digestion and cell separation: In a biosafety cabinet, transfer the tissue to a new sterile culture dish and wash with cold PBS to remove blood and debris; cut the tissue into 1-2 mm 3 Add digestion solution to the cells and stir at 37°C, 60-100 rpm for 1-2 hours. Add Trypsin-EDTA in the last 15 minutes of stirring to dissociate the cells.
[0009] S3, cell collection and culture, filtering the digestion solution, neutralizing it with RPM I-1640 medium, collecting the cell precipitate by centrifugation, resuspending the cells, inoculating the cell suspension into a collagen-coated culture flask, and placing the culture flask in an oxygen incubator to simulate the oxygen environment in tumor tissue and promote cell growth and adaptation;
[0010] S4, gene editing and functional studies, using the CRISPR-Cas9 system to edit specific genes, designing sgRNA and transfecting cells, and screening for successfully edited cell populations;
[0011] S5. Establishment of 3D culture model: Cultivate cells in low-adhesion culture dishes to form 3D spheroids and observe their behavior and drug response in the three-dimensional structure;
[0012] S6. Single-cell analysis and cell heterogeneity studies, using flow cytometry to separate single cells and perform single-cell RNA sequencing, i.e., scRNA-seq analysis, to study cell heterogeneity and its functional manifestations in tumors;
[0013] S7. Culture and subculture: Change the culture medium every 2 to 3 days and subculture according to cell growth to maintain cell viability and stability.
[0014] Preferably, the digestive solution in S2 is composed of 1-2 mg / ml collagenase IV and 0.25% trypsin-EDTA.
[0015] Preferably, the centrifugal condition in S3 is 12000-15000 rpm for 10-15 seconds.
[0016] Preferably, the parameters of the oxygen incubator in S3 are 1% to 5% O 2 Concentration, temperature 4 to 35 degrees Celsius.
[0017] Preferably, the digestion solution filtering means in S3 is filtering using a 70 μm cell filter.
[0018] Preferably, the RPMI-1640 medium in S3 contains 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.
[0019] Preferably, the sgRNA design steps in S4 are as follows:
[0020] Select the PAM sequence: clarify the target gene to be edited and its location. The PAM (Protospacer Adjacent Mot if) sequence on the genomic DNA recognized by the Cas9 protein is NGG;
[0021] Design sgRNA sequence: Use online SgRNA design tools or refer to existing literature to design SgRNA based on the target gene sequence and PAM sequence, ensure that the SgRNA sequence matches the common region of the exons of the target gene and is close to the start codon, and design 10 SgRNAs for each gene to increase the success rate of editing; for a specific gene, 5 SgRNAs are designed, SgRNA1 to SgRNA5, each SgRNA targets a different position of the gene.
[0022] Preferably, the steps of sgRNA synthesis and transfection in S4 are as follows:
[0023] Synthetic SgRNA: The SgRNA is efficiently synthesized using a chemical synthesis platform to ensure that the sequence is 100% correct and has functional protein knockout ability. In order to improve the stability of the SgRNA and reduce off-target effects, three thio and methoxy modifications are added to the 5' and 3' ends of the SgRNA;
[0024] Construction of sgRNA library: The designed sgRNA is synthesized into an ol igo pool, and then constructed into a CRISPR vector through enrichment and cloning;
[0025] Transfect cells: Select appropriate cell types and culture conditions, and package the constructed CRISPR plasmid library into lentivirus for downstream cell infection experiments.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] (1) The present invention uses collagen-coated culture bottles and adapted culture medium formulas, which help maintain the healthy state of primary urinary tumor cells and ensure their stability and repeatability during the culture process; through hypoxic culture conditions, the hypoxic environment in tumor tissue is simulated, which promotes cell growth and adaptability, making the cultured cells more consistent with the characteristics of the actual tumor microenvironment.
[0028] (2) The present invention utilizes the CRISPR-Cas9 system for gene editing, which can accurately study the functions and regulatory mechanisms of specific genes and reveal the key genes and pathways in tumor development; the establishment of a 3D spheroid model helps to more realistically simulate the structure and growth pattern of tumor tissue, providing a more accurate drug screening platform and biological behavior evaluation.
[0029] (3) The present invention uses single-cell RNA sequencing and other technologies to deeply analyze the cellular heterogeneity in urinary tumor cell populations, identify the phenotypic and molecular characteristics of different subpopulations, and provide a basis for personalized treatment and targeted treatment; test the sensitivity and resistance of different drugs, which helps to screen effective therapeutic drugs and evaluate the effectiveness of treatment plans, providing an experimental basis for clinical application. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 The present invention is a flow chart of a method for culturing primary cells of urinary system tumors. DETAILED DESCRIPTION
[0031] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0032] Embodiment 1:
[0033] See also Figure 1 As shown, a method for culturing primary cells of urinary system tumors comprises the following steps:
[0034] S1. Tissue sample collection and processing: obtain urinary tract tumor tissue from surgery, place the tissue in a sterile container containing cold PBS, and quickly send it to the laboratory;
[0035] S2, tissue digestion and cell separation, in a biosafety cabinet, transfer the tissue to a new sterile culture dish and wash with cold PBS to remove blood and debris; cut the tissue into 1 mm 3 The cells were detached into a block of 100 μl and digestion solution was added. The digestion solution consisted of 1 mg / ml collagenase IV and 0.25% trypsin-ethylenediaminetetraacetic acid (Trypsin-EDTA). The mixture was stirred at 37°C and 100 rpm for 1 hour. In the last 15 minutes of stirring, Trypsin-EDTA was added to dissociate the cells.
[0036] S3. Cell collection and culture. The digestion solution was filtered using a 70 μm cell strainer and neutralized with RPMI-1640 medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. The cell pellet was collected by centrifugation at 15,000 rpm for 15 seconds. The cells were resuspended and the cell suspension was inoculated into a collagen-coated culture flask. The culture flask was placed in an oxygen incubator with a parameter of 3% O 2 concentration, and a temperature of 8 degrees Celsius, simulating the oxygen environment in tumor tissue, promoting cell growth and adaptation;
[0037] S4, gene editing and functional studies, using the CRISPR-Cas9 system to edit specific genes, designing sgRNA and transfecting cells, and screening for successfully edited cell populations;
[0038] S5. Establishment of 3D culture model: Cultivate cells in low-adhesion culture dishes to form 3D spheroids and observe their behavior and drug response in the three-dimensional structure;
[0039] S6. Single-cell analysis and cell heterogeneity studies, using flow cytometry to separate single cells and perform single-cell RNA sequencing, i.e., scRNA-seq analysis, to study cell heterogeneity and its functional manifestations in tumors;
[0040] S7. Culture and subculture: Change the culture medium every 3 days and subculture according to cell growth to maintain cell viability and stability.
[0041] Specifically, the SgRNA design steps in S4 are as follows:
[0042] Select the PAM sequence: clarify the target gene to be edited and its location. The PAM (Protospacer Adjacent Mot if) sequence on the genomic DNA recognized by the Cas9 protein is NGG;
[0043] Design sgRNA sequence: Use online SgRNA design tools or refer to existing literature to design SgRNA based on the target gene sequence and PAM sequence, ensure that the SgRNA sequence matches the common region of the exons of the target gene and is close to the start codon, and design 10 SgRNAs for each gene to increase the success rate of editing; for a specific gene, 5 SgRNAs are designed, SgRNA1 to SgRNA5, each SgRNA targets a different position of the gene.
[0044] Specifically, the steps of SgRNA synthesis and transfection in S4 are as follows:
[0045] Synthetic SgRNA: The SgRNA is efficiently synthesized using a chemical synthesis platform to ensure that the sequence is 100% correct and has functional protein knockout ability. In order to improve the stability of the SgRNA and reduce off-target effects, three thio and methoxy modifications are added to the 5' and 3' ends of the SgRNA;
[0046] Construction of sgRNA library: The designed sgRNA is synthesized into an ol igo pool, and then constructed into a CRISPR vector through enrichment and cloning;
[0047] Transfect cells: Select appropriate cell types and culture conditions, and package the constructed CRISPR plasmid library into lentivirus for downstream cell infection experiments.
[0048] The test steps and data are as follows:
[0049] 1. Adaptability test under hypoxic culture conditions:
[0050] Steps: Place some cells in a hypoxic incubator, and some cells continue to be cultured under conventional culture conditions, compare the growth rate and morphological changes of cells in the hypoxic group and the conventional group, and evaluate their adaptability to the hypoxic environment;
[0051] The number of cells recorded every 24 hours, the data are as follows:
[0052] Day 1:1.2×10 5 ce lls;
[0053] Day 2: 2.5×10 5 ce lls;
[0054] Day 3:4.8×10 5 ce lls;
[0055] Cell morphology observation data:
[0056] The cell morphology is described using a microscope, such as the shape, size, and distribution of cytoplasmic contents of the cell. The data are as follows:
[0057] Cell shape: oval, about 15-20 μm in size;
[0058] Cytoplasmic inclusions: There are obvious granular structures in the cytoplasm;
[0059] 2. Gene editing and functional studies:
[0060] Perform gene editing, transfect cells and screen for successfully edited cell populations.
[0061] Evaluate functional differences between edited cells and wild-type cells, such as proliferation, invasion, and drug sensitivity, based on the experimental design;
[0062] The gene editing efficiency data are as follows:
[0063] PCR or sequencing data to verify gene editing efficiency:
[0064] Mutation frequency of target gene: about 30%;
[0065] Insertion / deletion frequency: insertion 20%, deletion 10%;
[0066] 3. Establishment and evaluation of 3D culture models:
[0067] Procedure: Cultivate cells in low-adhesion culture dishes to form 3D spheroids.
[0068] Time: Observe and measure the size, morphology, growth rate of 3D spheroids and their response to different drugs;
[0069] 3D sphere evaluation data:
[0070] Diameter or volume measurement data for a 3D sphere:
[0071] 3D sphere diameter on Day 7: 200 μm;
[0072] 3D sphere volume on Day 14: 5000 μm 3 ;
[0073] 4. Single cell analysis:
[0074] Steps: Use flow cytometry and other techniques to isolate single cells and perform single-cell RNA sequencing (scRNA-seq) analysis.
[0075] Time: Analyze single-cell transcriptome data in cell populations, identify differences in expression of different cell populations and functional genes, and explore cellular heterogeneity;
[0076] Analyze gene expression patterns in different cell populations:
[0077] Genes with increased expression in tumor cell subsets: CD44, MYC, CCND1;
[0078] Genes with increased expression in immune cells: CD3E, CD8A, I FNG;
[0079] 5. Drug sensitivity and resistance test data:
[0080] Measure drug effects using MTT or other cell viability assays:
[0081] IC50 value of drug A: 50 μM;
[0082] Drug B resistance index: 2 (relative to drug A resistance);
[0083] As can be seen from the above, the use of collagen-coated culture bottles and adapted culture medium formulas can help maintain the healthy state of urinary tumor primary cells and ensure their stability and repeatability during the culture process; through hypoxic culture conditions, the hypoxic environment in tumor tissue is simulated, which promotes cell growth and adaptability, making the cultured cells more consistent with the characteristics of the actual tumor microenvironment;
[0084] Gene editing using the CRISPR-Cas9 system can accurately study the functions and regulatory mechanisms of specific genes and reveal key genes and pathways in tumor development; establishing a 3D spheroid model helps to more realistically simulate the structure and growth pattern of tumor tissue, providing a more accurate drug screening platform and biological behavior evaluation;
[0085] Through technologies such as single-cell RNA sequencing, we can deeply analyze the cellular heterogeneity in urinary tract tumor cell populations, identify the phenotypic and molecular characteristics of different subpopulations, and provide a basis for personalized and targeted treatments; testing the sensitivity and resistance of different drugs will help screen effective therapeutic drugs and evaluate the effectiveness of treatment plans, providing an experimental basis for clinical applications.
[0086] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "examples", "specific examples" or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification and the features of different embodiments or examples, unless they are contradictory.
[0087] In the drawings of the embodiments disclosed in the present invention, only the structures related to the embodiments disclosed in the present invention are involved, and other structures can refer to the general design. In the absence of conflict, the same embodiment and different embodiments of the present invention can be combined with each other.
[0088] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A method for culturing primary cells of urinary system tumors, It is characterized in that The following steps are involved: S1. Tissue sample collection and processing: obtain urinary tract tumor tissue from surgery, place the tissue in a sterile container containing cold PBS, and quickly send it to the laboratory; S2, tissue digestion and cell isolation. In a biosafety cabinet, transfer the tissue to a new sterile culture dish and wash with cold PBS to remove blood and debris. Cut the tissue into 1-2 mm pieces 3 Add digestion solution to the cells and stir at 37°C, 60-100 rpm for 1-2 hours. Add Trypsin-EDTA in the last 15 minutes of stirring to dissociate the cells. S3, cell collection and culture, filtering the digestion solution, neutralizing it with RPMI-1640 medium, collecting the cell precipitate by centrifugation, resuspending the cells, inoculating the cell suspension into a collagen-coated culture flask, and placing the culture flask in an oxygen incubator to simulate the oxygen environment in tumor tissue and promote cell growth and adaptation; S4, gene editing and functional studies, using the CRISPR-Cas9 system to edit specific genes, designing sgRNA and transfecting cells, and screening for successfully edited cell populations; S5. Establishment of 3D culture model: Cultivate cells in low-adhesion culture dishes to form 3D spheroids and observe their behavior and drug response in the three-dimensional structure; S6. Single-cell analysis and cell heterogeneity studies, using flow cytometry to separate single cells and perform single-cell RNA sequencing, i.e., scRNA-seq analysis, to study cell heterogeneity and its functional manifestations in tumors; S7. Culture and subculture: Change the culture medium every 2 to 3 days and subculture according to cell growth to maintain cell viability and stability.
2. A method for culturing primary urinary system tumor cells according to claim 1, Features: The digestion solution in S2 is composed of 1-2 mg / ml collagenase IV and 0.25% trypsin-EDTA.
3. The method for culturing primary urinary system tumor cells according to claim 1, Features: The centrifugal conditions in S3 are 12000-15000 rpm for 10-15 seconds.
4. The method for culturing primary urinary system tumor cells according to claim 1, Features: The parameters of the oxygen incubator in S3 are 1% to 5% O 2 Concentration, temperature 4 to 35 degrees Celsius.
5. The method for culturing primary urinary system tumor cells according to claim 1, Features: The digestion solution in S3 was filtered using a 70 μm cell strainer.
6. The method for culturing primary urinary system tumor cells according to claim 1, Features: S3 medium RPMI-1640 medium contains 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.
7. The method for culturing primary urinary system tumor cells according to claim 1, Features: The steps for SgRNA design in S4 are as follows: Select the PAM sequence: clarify the target gene to be edited and its location. The PAM (Protospacer Adjacent Motif) sequence on the genomic DNA recognized by the Cas9 protein is NGG; Design sgRNA sequence: Use online SgRNA design tools or refer to existing literature to design SgRNA based on the target gene sequence and PAM sequence, ensure that the SgRNA sequence matches the common region of the exons of the target gene and is close to the start codon, and design 10 SgRNAs for each gene to increase the success rate of editing; for a specific gene, 5 SgRNAs are designed, SgRNA1 to SgRNA5, each SgRNA targets a different position of the gene.
8. The method for culturing primary urinary system tumor cells according to claim 1, Features: The steps for SgRNA synthesis and transfection in S4 are as follows: Synthetic SgRNA: SgRNA is synthesized using a chemical synthesis platform to ensure that the sequence is 100% correct and has functional protein knockout ability. In order to improve the stability of SgRNA and reduce off-target effects, three thio and methoxy modifications are added to the 5' and 3' ends of SgRNA respectively; Construction of sgRNA library: The designed sgRNA is synthesized into an oligo pool, which is then enriched and cloned and constructed into a CRISPR vector; Transfect cells: Select appropriate cell types and culture conditions, and package the constructed CRISPR plasmid library into lentivirus for downstream cell infection experiments.
Citation Information
Cited By
PDC (Polycrystalline Diamond Compact) cell carrying bar code DNA (Deoxyribonucleic Acid) tag library convenient to track as well as preparation method and application thereof
CN120574779A
